Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis

References

• Gossec L. Patient-Reported Outcomes in Rheumatoid Arthritis: why are They Important and How Should They Be Assessed? Turk J Rheumatol. 2010;25(3):99–104.
   Google Scholar
• Smolen J, Strand V, Koenig A, et al. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arth Res Therapy. 2016:18.
   Google Scholar
• Murphy L, Sacks JJ, Brady TJ, et al. Anxiety and depression among US adults with arthritis: prevalence and correlates. Arth Care Res. 2012;64:968–976.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Moore A, Vasilescu R, et al., A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 36(5): 685–695. 2016.
   PubMed Web of Science ®Google Scholar
• Rheumatoid Patient Foundation. Unmasking rheumatoid disease: the patient experience of rheumatoid arthritis. 2013. accessed 8/26/2021. https://rheum4us.org/wp-content/uploads/2013/04/Unmasking-Rheumatoid-Disease-The-Patient-Experience-of-Rheumatoid-Arthritis-White-Paper.pdf
   Google Scholar
• Strand V, Crawford B, Singh J, et al. Use of ”spydergrams” to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Annals of the Rheumatic Diseases. 2009;68(12):1800–1804.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Wallenstein G. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. J Rheumatol. 2010;37(8):1615–1625.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (Where Patient Level Data Are Not Available). Value Health. 2008;11(7):1131–1143.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Predicting the short form-6D Preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12(2):346–353.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Rat A-C, Guillemin F, et al. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Annals of the Rheumatic Diseases. 2012;71(9):1478–1483.
   PubMed Web of Science ®Google Scholar
• Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2014;44(2):123–130.
   PubMed Web of Science ®Google Scholar
• Bartlett S, Hewlett S, Bingham IIICO, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Ds. 2012;71:1855–1860. * Preliminary OMERACT definition of flares in RA
   Google Scholar
• Strand V, Wright G, Bergman M, et al. Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. J Rheumatol. 2015;42(11):11.
   PubMed Web of Science ®Google Scholar
• Hewlett S, Chalder T, Choy E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatol. 2011;50(6):1004–1006.
   PubMed Web of Science ®Google Scholar
• Loppenthin K, Esbensen BA, Jennum P, et al. Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clin Rheumatol. 2015;34(12):2029–2039.
   PubMed Web of Science ®Google Scholar
• Druce KL, Jones GT, Macfarlane GJ, et al. Determining pathways to improvements in fatigue in rheumatoid arthritis. Arth Rheum. 2015;67:2303–2310.
   PubMed Web of Science ®Google Scholar
• Louati K, Berenbaum F. Fatigue in chronic inflammation - a link to pain pathways. Arthritis Research & Therapy. 2015;17(1):254.
   PubMedGoogle Scholar
• Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatol. 2016;55(2):268–278.
   PubMed Web of Science ®Google Scholar
• Connolly D, Fitzpatrick C, O’Toole L, et al. Impact of Fatigue in Rheumatic Diseases in the Work Environment: a Qualitative Study. International Journal of Environmental Research and Public Health. 2015;12(11):13807–13822.
   PubMed Web of Science ®Google Scholar
• Benka J, Nagyova I, Rosenberger J, et al. Social participation in early and established rheumatoid arthritis patients. Disabil Rehabil. 2016;38(12):1172–1179.
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1(1):79.
   PubMedGoogle Scholar
• Cella D, LAI J-S, Stone A. Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) questionnaire. Support Care Cancer. 2011;19(9):1441–1450.
   PubMed Web of Science ®Google Scholar
• Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811–819.
   PubMed Web of Science ®Google Scholar
• Butt Z, Rao AV, Lai J-S, et al. Age-associated differences in fatigue among patients with cancer. J Pain Symptom Manage. 2010;40(2):217–223.
   PubMed Web of Science ®Google Scholar
• Montan I, Lowe B, Cella D, et al. General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. Value Health. 2018;21(11):1313–1321.
   PubMed Web of Science ®Google Scholar
• Strand V, Boers M, Idzerda L, et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response Criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38:1720–1727.
   Google Scholar
• Krishnan E, Sokka T, Hakkinen A, et al. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. Arth Rheum. 2004;50(3):953–960.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr., Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2® health survey. 2nd. Lincoln RI: QualityMetric Incorporated; 2007.
   Google Scholar
• Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Research & Therapy. 2015;17(1):307.
   PubMedGoogle Scholar
• Strand V, Kremer J, Gruben D, et al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arth Care Res. 2017;69(4):592–598.
   Web of Science ®Google Scholar
• Strand V, Pope J, Tundia N, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Research & Therapy. 2019;21(1):272.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or Adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Ds. 2017:1–9.
   Google Scholar
• Strand V, van Vollenhoven R, Lee EB, et al. Tofacitinib or Adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatol. 2016;55(6):1031–1041.
   PubMed Web of Science ®Google Scholar
• Strand V, Sun L, Ross Terres J, et al. FRI0048 number needed to treat to achieve minimum clinically significant differences in patient reported outcomes in patients treated with baricitinib. Ann Rheum Ds. 2020;79:580–600.
   Web of Science ®Google Scholar
• Strand V, Tundia N, Wells A, et al. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatol. 2021;60(7):3209–3221.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kremer J, Gaich CL, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Ds. 2016:1–7.
   Google Scholar
• Strand V, Sun L, Ross Terres J, et al. Number needed to treat to achieve minimum clinically significant differences in patient-reported outcomes in patients treated with Baricitinib. EULAR. 2020. Abstract FRI0048. https://doi.org/10.11136/annrheumdis-2020-eular.1440.
   Google Scholar
• Strand V, Burmester GR, Zerbini CAF, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arth Care Res. 2015;67(4):475–8310.
   Web of Science ®Google Scholar
• Strand V, Schiff M, Tundia N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Research & Therapy. 2019;21(1):263.
   PubMed Web of Science ®Google Scholar
• Genovese M, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. NEJM. 2016;374(13):1243–1245.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles -Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524.
   PubMed Web of Science ®Google Scholar
• Schiff M, Takeuchi T, Fleischmann R, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Research & Therapy. 2017;19(1):208.
   PubMedGoogle Scholar
• Turk DC, Dworkin RH, McDermott MP, et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assement in clinical trials. Pain. 2008;139(3):485–493.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121.
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Aldington D, et al. Pain measures and cut-offs - ‘no worse than mild pain’ as a simple, universal outcome. Anaesthesia. 2013;68(4):400–412.
   PubMed Web of Science ®Google Scholar
• Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2(2):e000308.
   PubMedGoogle Scholar
• Taylor P, Kavanaugh A, Nash P, et al. Effect of Filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials [abstract]. Arthritis Rheumatol. 2020;72(suppl 10). Available from: https://acrabstracts.org/abstract/effect-of-filgotinib-on-pain-in-patients-with-rheumatoid-arthritis-results-from-phase-3-clinical-trials/
   Google Scholar
• Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or Adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76(11):1853–1861.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Lee YC, Fleischmann R, et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM Trial. J Clin Med. 2019;8(6):831–841.
   Web of Science ®Google Scholar
• Fautrel B, Kirkham B, Pope JE, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J Clin Med. 2019;8(9):1394.
   Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):e347–57.
   Google Scholar
• Strand V. Viewpoint: RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors? RMD Open. 2021;7(1):e001565.
   PubMed Web of Science ®Google Scholar
• Giles JT, Sattar N, Gabriel S, et al. Cardiovascular Safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis & Rheumatology. 2020;72(1):31–40.
   PubMed Web of Science ®Google Scholar
• Pfizer. Pfizer shares co-primary endpoint results from post-marketing. [ Accessed 27 Jan 21]. Available: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-postmarketing
   Google Scholar
• European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC). Recommendations on Signaling. 5 July. [ Accessed 10 June 21]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendationssignals/2021.adopted-7-10-june-2021-prac-meeting_en.pdf
   Google Scholar
• Food and Drug Administration Drug Safety Communication: FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. [ Accessed 1 Sept 21]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-aboutincreased-risk-serious-heart-related-events-cancer-blood-clots-and-death
   Google Scholar
• Pincus T, Strand V, Koch G, et al. An index of the three core data set patient questionnaire measuresdistinguishes efficacy of active treatment from that of placebo as effectively as the american college of rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arth Rheum. 2003;48:625–630.
   PubMed Web of Science ®Google Scholar
• Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arth Care Res. 2010;62:181–189.
   Web of Science ®Google Scholar
• Pincus T, Furer V, Keystone E, et al. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arth Care Res. 2011;63:1142–9. .
   PubMed Web of Science ®Google Scholar
• Strand V, Bong Lee E, Yazici Y, et al. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clin Rheumatol. 2018;37(8):2043–2053.
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, Castrejon I. Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care. Bull NYU Hosp Joint Dis. 2012;70(1):30–6. .
   PubMedGoogle Scholar
• Gossec L, Dougados M, Rincheval N, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Annal Rheumatic Diseases. 2009;68(11):1680–1685.
   PubMed Web of Science ®Google Scholar
• Gossec L, Strand V, Proudfoot C, et al. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. J Rheumatol. 2019;46(10):1259–1267.
   PubMed Web of Science ®Google Scholar
• Dougados M, Brault Y, Logeart I, et al. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Research & Therapy. 2012;14(3):R129. .
   PubMed Web of Science ®Google Scholar
• Simon LS, Taylor PC, Choy EH, et al. The JAK/STAT pathway: a focus on pain in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 2021;51(1):278–284.
   PubMed Web of Science ®Google Scholar
• Strand V, Kaine J, Alten R, et al. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis Research & Therapy. 2020;22(1):243.
   PubMed Web of Science ®Google Scholar